SEC Form 4 · accession 0001179110-15-016438
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan M Peacock
Officer — President and CEO · Director
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 15, 2015 | P | 7,500 | $2.72 | A | 38,927 | D | |
| Common StockF2 | Dec 16, 2015 | P | 12,800 | $2.7606 | A | 51,727 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $2.50 to $2.85 per share. The reporting person hereby undertakes upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F2The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $2.67 to $2.965 per share. The reporting person hereby undertakes upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.